rapamycin


Also found in: Medical, Wikipedia.

rap·a·my·cin

 (răp′ə-mī′sĭn)
n.

[From Rapa (Nui) (Easter Island), where the soil sample containing the actinomycete producing sirolimus was obtained + -mycin.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
eRapa is targeted specifically to the gastrointestinal tract and is delivered at a consistent and lower dosage than generic rapamycin, not only reducing toxicity, but also capitalising on the potential of partial inhibition of the mechanistic target of rapamycin to act as a cancer immuno-oncology and chemopreventative agent.
ResTORbio announced additional data from the Phase 2b clinical trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1.
Researchers believe many of the findings will be relevant to human aging, including intervention with the drug rapamycin.
ISLAMABAD -- Rapamycin and drugs that act like it have a limited effect against many cancers because their tumors are resistant to them.
In this study, we aimed to investigate the mechanisms of rapamycin on the pain sensitization of model mice by in vivo experiments to explore the effect of mammalian target of rapamycin (mTOR) in the pathogenesis of neuropathic pain caused by NRTIs.
Patients in the ongoing Phase 2 trial of SEL-212, designed to be the first non-immunogenic version of uricase, received three monthly doses of up to 0.15 mg/kg of SVP Rapamycin with 0.2 or 0.4 mg/kg of pegsiticase, followed by two monthly doses of pegsiticase alone.
FRIDAY, June 8, 2018 (HealthDay News) -- Topical rapamycin seems effective for tuberous sclerosis complex (TSC)-related facial angiofibromas, according to a study published online May 23 in JAMA Dermatology.
Selecta Biosciences have developed synthetic vaccine particles encapsulating rapamycin (SVP-Rapamycin) that have been shown to mitigate immunogenicity against a variety of biologic drugs by inducing tolerogenic dendritic cells and antigen-specific regulatory T cells.
The results suggest that there may be a role for mammalian target of rapamycin inhibitors in the conservative management of endometrial cancer.
The team treated the cells with rapamycin, an mTOR inhibitor that is already used clinically in TSC to reduce the size of TSC-related tumors and prevent TSC-related seizures.
mTORC1 is composed of regulatory-associated protein of mTOR (RAPTOR), proline-rich AKT substrate 40 kDa (PRAS40), mammalian lethal with Sec-13 protein 8 (mLST8) and DEP domain TOR-binding protein (DEPTOR), and it is inhibited by rapamycin, a macrolide produced by the bacterium Streptomyces hygroscopicus (Figure 1(a)).